Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments
NonrulemakingNoticeFDA-2026-N-3947-0001
Comments
16
Awaiting comments
Deadline
17 days
Closes Jul 1, 2026
Net support
+13%
Support minus oppose · campaigns included
+13% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- May 1, 2026
- Comment period
- May 1, 2026 – Jul 1, 2026
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-08524
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 16 of 16 comments
100%· analysis complete
Stance breakdown
+13%
Net support
Support8Oppose6Other2
Showing organic comments only. With campaigns included, net support is +13%.
Who commented
Breakdown by commenter type, organic comments only.
Academic
1
Advocacy
4
Individual
11
Comments over time
Weekly arrivals, stacked by stance, organic only.
Posted May 1, 2026Deadline Jul 1, 2026
Support8Oppose6Other2
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 16 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.